Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KSWW-I do believe we'll have a multiday run and will av up on dips.I don't think the dip will last long as more people will try to get in.IMO
KSWW -It can go on multiday from here cuz the Sp still hasn't catch up to the fundamentalas.IMO
KSWW is ready to break with strong vol.
LBIX +40% 3.9
In NAVX-5.58
Novavax's Head Of Vaccine Research To Participate In WHO Meeting To Develop Global Action Plan For Pandemic Influenza
PR Newswire - May 01, 2006 09:27
MALVERN, Pa., May 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that its Vice President of Vaccine Research, Dr. Rick Bright, will participate in the World Health Organization (WHO) meeting for the development of a global action plan for increasing pandemic vaccine supply to develop a plan to alleviate the global shortage of pandemic influenza vaccines. Dr. Bright will join leading scientists, industry, and public health experts from around the world at the meeting, to be held this week at WHO headquarters in Geneva, Switzerland.
"I am extremely pleased to have been invited to participate in this important meeting," Dr. Bright said. "A dialogue between researchers, industry, and public health experts is the best way to develop an approach to protect people around the world from the potentially debilitating effects of influenza." Dr. Bright has more than 15 years of experience as a researcher and is an expert on influenza vaccine and antiviral research, one of a handful of such experts in the world. Prior to joining Novavax in February, 2006, he served at the Centers for Disease Control (CDC) and Prevention in Atlanta, GA.
Representatives from national immunization programs, regulatory authorities, and vaccine manufacturers from both industrialized as well as developing countries also will participate in the meeting. More information on the meeting can be obtained from the WHO website at http://www.who.int/csr/disease/influenza/vaccinesconsult2006/en/index.html
LBIX is running.
KSWW I will hold for low double digits 12-13 and it will get there soon.FIx is selling 1 X rev and we are only 1/2 of rev and the momo will carry us higher ( low float).IMO
I rather own KSWW even if they have same fundamentals cuz KSWW hasnt been on big boys' radar yet and it will move up quicker once it hit theirs.I think the traders start to get notice it now.
http://search.messages.yahoo.com/search/messages?tag_M=ksww&fname_M=txt_main
KSW(W)I think it's just a starting to get notice by traders .It will have more room to go from here i think low double digits is doable in the next 3 months.IMO
MZT -Yep i still have them. .
KSWW i av up in the last 2 days .
MT ,remember RELM(RWC) it went up 250% after it moved to AMEX.
KSWW is another on will be on AMEX next wed.The big boys will buy their shares up,read their news.Low OS and Float is tight
and I have a boat load of them.
http://www.investorshub.com/boards/board.asp?board_id=5445
RWC (relm) i made another 250% after it went to AMEX.Hold on for the whole enchilada.This is a double digits stock.IMO
http://www.investorshub.com/boards/quotes.asp?ticker=rwc&qm_page=84853&qm_symbol=RWC
http://www.investorshub.com/boards/board.asp?board_id=4519
I just updated the i-box.Anyone here has any interest to be an assistant of the i-box? Let me know and i will ad your name on it.
NICE
ELSE is on fire ,I'm not in.
NPSP -European Commission Issues Marketing Authorization for Preotact(R) (PREOS(R))
PR Newswire - April 26, 2006 09:25
Therapy Approved for the Treatment of Postmenopausal Osteoporosis
SALT LAKE CITY and ROSKILDE, Denmark, April 26, 2006 /PRNewswire-FirstCall via COMTEX/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) (www.npsp.com) and its partner Nycomed (www.nycomed.com) announced today that the European Commission has granted marketing authorization for Preotact (parathyroid hormone [rDNA origin] for injection). Preotact is the European brand name for PREOS which NPS licensed to Nycomed in 2004 for development and marketing in Europe.
The EMEA approved Preotact for treatment of postmenopausal women with osteoporosis at high risk for fractures. More information will be available in the coming days on the EMEA website at www.emea.eu.int.
"We congratulate Nycomed on reaching this major milestone and look forward to the launch of Preotact in Europe later this year," said Hunter Jackson, Ph.D., NPS chairman and CEO. "This is a significant event for NPS and our partner Nycomed and for the women who will benefit from its efficacy advantages."
"Preotact is a valuable addition to our osteoporosis product portfolio. We are gratified by the European Commission's agreeing that Preotact provides a safe, effective, and user-friendly treatment option for patients suffering from post menopausal osteoporosis." said Hakan Bjorklund, Nycomed CEO.
Nycomed submitted the marketing authorization application for Preotact to the European Medicines Evaluation Agency (EMEA) in March, 2005. The marketing authorization for Preotact is valid in all 25 member states of the European Union. Nycomed is now preparing for the pan-European launch of Preotact, scheduled for second half of 2006. NPS Pharmaceuticals filed a new drug application for clearance to market PREOS in the U.S. with the U.S. Food and Drug Administration in May of 2005 and received an approvable letter in March of 2005.
About the Product
PREOS/Preotact is recombinant human parathyroid hormone. NPS has studied PREOS in a number of clinical settings to document its safety and effects on bone. The pivotal Phase 3 study, known as TOP (Treatment of Osteoporosis with PTH), was a multi-center, randomized, double-blind and placebo-controlled clinical trial designed to evaluate the potential of PTH to reduce the risk of first and subsequent vertebral fractures in post-menopausal women.
In the TOP study PREOS demonstrated a statistically significant reduction in the risk of new vertebral fractures in women with and without pre-existing osteoporosis-related fractures. Results from the TOP study have been the foundation of both the E.U. and the U.S. marketing authorization applications.
About NPS Pharmaceuticals
re INB -NP, Mick .GLTY
I'm not in CBMX..The bird flu hype has gone.
Hi there Mick ..INB is going to be good one.
INB -Integrated BioPharma, Inc.'s Wholly Owned Subsidiary, AgroLabs, Inc., to Supply Ralphs Grocery Company With Three of Its Healthful Products from Its Proprietary Nutraceutical Beverage Line
HILLSIDE, N.J., April 25 /PRNewswire-FirstCall/ -- AgroLabs, Inc., a wholly owned subsidiary of Integrated BioPharma, Inc. (Amex: INB), announces the beginning of its relationship with Ralphs Grocery Company stores in Southern California. Three of its healthful Naturally juice supplements will be available in 115 of Ralphs' stores starting the first week of May 2006.
Ralphs is a division of The Kroger Co., one of the nation's largest grocery retailers, with fiscal 2005 sales of $60.6 billion.
Kurt E. Cahill, chief operating officer of AgroLabs, stated, 'Ralphs will be carrying our Naturally Noni, Naturally Pomegranate and Naturally Thai Mangosteen beverages all in 16 fluid ounce bottles. We are pleased to add the Ralphs Southern California stores to our growing list of retail outlets that are offering our superfruit liquid supplements. This reflects America's continuing thirst for health-oriented products.'
E. Gerald Kay, Chief Executive Officer of INB, added, 'AgroLabs continues to expand the availability of its liquid, healthful, nutritional products. The addition of Ralphs expands our retail distribution channels which currently include Costco, Wal-Mart, Sam's Clubs and BJ's Wholesale Club stores. Our AgroLabs subsidiary continues to focus on building broad distribution of our product lines and our identity as a leading provider of healthful nutritional products.'
AgroLabs, Inc. distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most recently, Acai Extreme Energy. These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. Additional information on AgroLabs and its products can be obtained from its website at http://www.agrolabs.com or by calling (817) 410-2140.
About Integrated BioPharma Inc. (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at http://www.iBioPharma.com.
INB -Integrated BioPharma, Inc.'s Wholly Owned Subsidiary, AgroLabs, Inc., to Supply Ralphs Grocery Company With Three of Its Healthful Products from Its Proprietary Nutraceutical Beverage Line
HILLSIDE, N.J., April 25 /PRNewswire-FirstCall/ -- AgroLabs, Inc., a wholly owned subsidiary of Integrated BioPharma, Inc. (Amex: INB), announces the beginning of its relationship with Ralphs Grocery Company stores in Southern California. Three of its healthful Naturally juice supplements will be available in 115 of Ralphs' stores starting the first week of May 2006.
Ralphs is a division of The Kroger Co., one of the nation's largest grocery retailers, with fiscal 2005 sales of $60.6 billion.
Kurt E. Cahill, chief operating officer of AgroLabs, stated, 'Ralphs will be carrying our Naturally Noni, Naturally Pomegranate and Naturally Thai Mangosteen beverages all in 16 fluid ounce bottles. We are pleased to add the Ralphs Southern California stores to our growing list of retail outlets that are offering our superfruit liquid supplements. This reflects America's continuing thirst for health-oriented products.'
E. Gerald Kay, Chief Executive Officer of INB, added, 'AgroLabs continues to expand the availability of its liquid, healthful, nutritional products. The addition of Ralphs expands our retail distribution channels which currently include Costco, Wal-Mart, Sam's Clubs and BJ's Wholesale Club stores. Our AgroLabs subsidiary continues to focus on building broad distribution of our product lines and our identity as a leading provider of healthful nutritional products.'
AgroLabs, Inc. distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most recently, Acai Extreme Energy. These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. Additional information on AgroLabs and its products can be obtained from its website at http://www.agrolabs.com or by calling (817) 410-2140.
About Integrated BioPharma Inc. (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at http://www.iBioPharma.com.
CombiMatrix and INBIO Forming Marketing and Sales Arm In Europe
Business Wire - April 26, 2006 06:00
NEWPORT BEACH, Calif., Apr 26, 2006 (BUSINESS WIRE) -- Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group is collaborating with INBIO on the formation of a marketing and sales arm for Europe for CombiMatrix CustomArray(TM) products. The entity, "CombiMatrix Europe GmbH," is based in Freiburg, Germany. CombiMatrix Europe GmbH will begin by serving specifically Germany, the United Kingdom, Switzerland, and Austria. The new entity is making its first appearance at the Analytica 2006 conference currently underway in Munich.
"CombiMatrix's goal is to aggressively expand its marketing and sales through partnerships and distribution deals," said Dr. Amit Kumar, President and CEO of CombiMatrix. "We already have distribution deals in place with INBIO and have been extremely pleased with their progress and expertise. CombiMatrix Europe expands this relationship to Europe, where CombiMatrix and INBIO see considerable opportunity and expansion."
"We are delighted to launch CombiMatrix Europe GmbH and anticipate a rapid uptake of CustomArray products within Europe. Importantly, our European customers will benefit significantly via the improved access to this unique microarray technology. The timing is perfect given recent and imminent advances in the capability of the CustomArray platform," said Mark Humble, CEO of INBIO.
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.
The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.
Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.
Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.
ABOUT INBIO
INBIO is the Life Science arm of BioInsight Pty Ltd and provides comprehensive distribution coverage for the Australian and New Zealand Life Science market for its international partners. INBIO's international expansion into Asia and Europe is providing the basis for strategic collaborations well beyond its initial foundation.
With a highly experienced commercial team, our focus is on providing innovative solutions for gene expression analysis. INBIO has formed distribution alliances with a range of organizations to satisfy our customers' demand for such products in this growing market segment. For more information on INBIO, visit our website at http://www.inbio.com.au.
I saw that and don't trust it.I'll pass .TY
SO which is the correct one ?TY
I'm out ADM.. My MGPI is on fire .I have a boat load of them it's still cheap vs PEIX and ADM.
I'm in ADM 38.57..peix and mgpi are on fire.
ADM Plans Groundbreaking Ceremony Today for First Wholly-Owned Biodiesel Plant in North Dakota, an Industrial Info News Alert
Business Wire - April 24, 2006 08:07
SUGAR LAND, Texas, Apr 24, 2006 (BUSINESS WIRE) -- Researched by Industrial Info Resources (Sugar Land, Texas). Agriprocessing giant Archer Daniels Midland Company (NYSE:ADM) has announced plans for a ceremonial silver shovel groundbreaking event today on the company's first wholly-owned biodiesel production plant in North Dakota.
For details, view the entire article by subscribing to Industrialinfo.com's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=85080, or browse other breaking industrial news stories at www.industrialinfo.com.
Industrial Info Resources (IIR) is a Marketing Information Service company that has been doing business for over 23 years. IIR is respected as the leader in providing comprehensive market intelligence pertaining to the industrial processing, heavy manufacturing, and energy-related industries throughout the world. For more information send inquiries to synfuelsgroup@industrialinfo.com or visit us at www.industrialinfo.com.
KSW, Inc. Awarded $16,000,000 Project
Business Wire - April 24, 2006 09:00
LONG ISLAND CITY, N.Y., Apr 24, 2006 (BUSINESS WIRE) -- KSW, Inc. (Over-The-Counter Bulletin Board: KSWW.OB). KSW, Inc. announced today that it has been awarded a contract to furnish and install the HVAC systems in a mixed-use building along the Brooklyn waterfront. The former Watchtower Building will be converted into retail shops and luxury condominiums overlooking the New York Harbor. KSW has specialized in this type of conversion on multiple projects in lower Manhattan, including a project at 270 Broadway for the same owner. KSW's work at this new project is valued at approximately $16,000,000, and will take 2 years to complete.
KSW's CEO, Floyd Warkol, commented that: "Our value engineering services enabled us to show the owner how to offer a first class HVAC system at the lowest practical cost."
With this project, the Company's current backlog of work is approximately $100,000,000.
same here .GL
ARTX .60-75 ST.
CombiMatrix Molecular Diagnostics Launches and Ships First Microarray Diagnostic Product Ahead of Schedule
Business Wire - April 21, 2006 06:00
NEWPORT BEACH, Calif., Apr 21, 2006 (BUSINESS WIRE) -- Acacia Research Corporation (NASDAQ:CBMX) (NASDAQ:ACTG) announced today its CombiMatrix group's subsidiary CombiMatrix Molecular Diagnostics (CMDX) has begun shipment of its first diagnostic microarray product.
"This product, developed in conjunction with Array Genomics of France, has been designed to detect genomic copy number variations associated with constitutional chromosome imbalances as well as with those associated with over 40 defined genetic diseases and syndromes, such as DiGeorge and William's syndromes," said Dr. Mansoor Mohammed, CSO and Vice President of CMDX. "The more we learn about the heterogeneity with which specific genetic syndromes can be manifested, the more we begin to appreciate the need for array CGH in aiding more accurate differential diagnoses."
Roughly two thirds of patients, mostly children, who exhibit genetic developmental disorders are currently undiagnosed due to the lack of technology for such diagnosis. This inability to diagnose the underlying cause of the disorder makes it difficult to provide appropriate medication or useful genetic counseling. Our array, which can be used for pre- and post-natal analysis, will provide much greater genetic information for diagnosing and treating these disorders, than is available through conventional cytogenetic testing. This array is the first of several arrays in our pipeline that will help to enable the era of personalized medicine based on a genetic analysis of individual patients.
"We are pleased to have launched our first product ahead of schedule," stated Matt Watson, CEO of CMDX. "We began shipping this product to Europe this week. We will require FDA approval before we can sell the arrays for diagnostic applications in the U.S. This regulatory hurdle will not prevent us from selling the arrays domestically for research purposes, however. Also, now that we have achieved our CLIA certification, we will soon begin offering genetic testing services in our clinical laboratory. This quarter our clinical services will be based on this CGH array, and in the late third quarter of this year we will begin providing melanoma (skin cancer) diagnosis and typing services to our customers."
ABOUT ACACIA RESEARCH CORPORATION
Goog is still too strong to short.I wouldn't stand in front the train yet .
CHCG - China 3C Group Signs Sales Agent Agreement for Panasonic Projectors
Friday April 21, 8:00 am ET
ZHEJIANG, China, April 21 /PRNewswire-FirstCall/ -- China 3C Group (OTC Bulletin Board: CHCG.OB - News), the parent company of two established electronic product distributors in Eastern China today announced that the Company has signed a sales agent agreement with Shanghai Hansen Office Appliance Company Limited, Shanghai, China, the authorized supplier of Panasonic projectors in Eastern China.
Under the terms of the agreement, China 3C Group will be an authorized sales agent of Panasonic projectors in Eastern China. The contract was effective as of April 20, 2006 and will run for one year. The Company will be selling models P1S12, U1X68, P1SDC and U1S70.
Mr. Zhenggang Wang, Chief Executive Officer, stated, "We are most pleased to have been designated as a sales agent for Panasonic projectors in Eastern China. This is a new product for us and it will extend our current product offerings to both existing and potential customers. The influx of foreign enterprises along with office modernization in Eastern China provides excellent market potential for projectors and we anticipate that this new product introduction will add to our revenues in 2006."
About China 3C Group
China 3C Group is a large-scale enterprise integrating the selling, circulation and modern logistics of 3C product (Communication Product, information technology products and digital products) in China through its two subsidiaries: Yiwu Yong Xin Telecommunication Company Limited, which is an authorized sales agent, focusing on the selling, circulation and modern logistics of fax machines and cord phone products in China, and Hangzhou Wang Da Electronics Company Limited, which is an authorized sales agent focusing on the selling, circulation and modern logistics of cell phones, cell phone products, IT products (including notebook or laptop computers), and digital products (including digital cameras, digital camcorders, MP3 players, PDA, flash disks, and removable hard disks) in China.
They 're both looking good but for LT i think MGPI is a better play it's more diversified.They also produce special ingredients for the low carb food (remember ATKIN DIET).MGPI went north of 20 because of that fad.
http://www.mgpingredients.com/
Yep it 's hard to trade when it's such a big gap.
It's an invalid symbol on Yhoo they changed CLME to NWRT . TY
SO what's the symbol ? CLME ,NWRT .TIA
I'm out of GSHF for a small gain(INSQ<VRDM) ..they are way overbot.IMO
Ty MT i bot some GHSF.
OTD - O2Diesel Adds an Additional $6.5 Million of Funding and Highlights Fiscal Year 2005 Results
Thursday April 20, 9:04 am ET
NEWARK, DE--(MARKET WIRE)--Apr 20, 2006 -- O2Diesel Corporation (AMEX:OTD - News), a pioneer in the development of cost-effective, cleaner-burning, diesel fuels for centrally fueled fleets of all types, today announced the highlights of the Company's financial results for the year ended December 31, 2005. The Company is also pleased to announce the signing of two agreements for $6.5 million of additional financing.
Year-end Results:
For the fiscal year ended December 31, 2005, the Company reported revenues of $195,607 as compared to revenues of $127,451 for the same period of 2004, while showing sequential improvements on a quarterly basis throughout 2005. The Company reported a net loss of $7.5 million, or ($0.22) per share for the year ended December 31, 2005 as compared with a net loss of $6.7 million, or ($0.23) per share for the same period of 2004.
At December 31, 2005, the Company had nearly $5 million on the balance sheet consisting of $1.4 million in cash and cash equivalents and $3.5 million in restricted cash, compared to $1.2 million from a year ago. Working capital stands at $3.8 million compared to a negative working capital of ($106,693) a year ago. Shareholders equity stood at approximately $4.0 million at year-end 2005 compared to $141,000 at the end of 2004. These results do not include the recent agreements for $6.5 million of financing.
The Company's independent registered public accounting firm has inserted an explanatory paragraph related to a going concern uncertainty into their Audit Report in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005 noting that the Company will require additional equity to continue as a going concern. As a result the Company has recently entered into agreements for $6.5 million of financing and is working toward completing an additional financing to have the going concern removed from future filings.
The Company has been pursuing various equity investments and following discussions over several weeks it has entered into two separate agreements on April 6, 2005. The first is a Common Stock and Warrant Purchase Agreement with UBS AG London (www.UBS.com) for 5,333,333 shares of its common stock, for total proceeds of $4,000,000. As part of this sale, the company will also issue warrants to purchase 2,666,667 shares of common stock at an exercise price of $0.825 per share. The warrants expire forty-two months after the date of issuance.
The second independent Common Stock and Warrant Purchase Agreement was also entered into on April 6, 2005 with Standard Bank PLC London (www.standardbank.com), for 3,333,333 shares of its common stock, for total proceeds of $2,500,000. As part of this sale, the company will also issue warrants to purchase 1,666,667 shares of common stock at an exercise price of $0.825 per share. The warrants expire forty-two months after the date of issuance.
The company anticipates that these financings will close within 30 days.
"As indicated in our Form 10-KSB and previous filings, we intended to raise additional capital in 2006 in order to meet our ongoing working capital needs and meet our shareholder equity requirements," said Alan Rae, O2Diesel's President and CEO. "We are very pleased to secure both of these investments from such recognized institutions adding to our institutional shareholders base and it further confirms that we are firmly on the way to securing the funds we need to execute our business plan."
"Over the course of the previous year we have reached several key milestones, while reaching the first anniversary of O2Diesel(TM)'s use at a number of our customers with positive feedback and results to date. Our relationship with Abengoa, Europe's largest BioEthanol producer, to develop and market our O2Diesel fuel in Europe coupled with the growing need in the US to develop alternative fuels has greatly enhanced the Companies exposure over the past year and further confirmingO2Diesel(TM) as a viable, commercial, clean burning and renewable alternative to regular diesel fuel for centrally fueled fleets in the US and abroad."
More About O2Diesel: The Company and Its Fuel Technology
O2Diesel Corporation (AMEX:OTD - News) and its U.S. subsidiary O2Diesel, Inc., is a pioneer in the commercial development of a cleaner-burning diesel fuel alternative that provides exceptional performance and environmental qualities for centrally fueled fleets and off-road equipment of all kinds. Engineered and designed for universal application, O2Diesel(TM) is an ethanol-diesel blend that substantially reduces harmful emissions without sacrificing power and performance. Extensive independent and government-recognized laboratory and in-use field tests have demonstrated the effectiveness of O2Diesel(TM) -- the introduction of this cost-effective, cleaner-burning diesel fuel is now underway in the United States and other global markets. For more information please refer to www.o2diesel.com.